Literature DB >> 17146153

Decreases in serum triacylglycerol and visceral fat mediated by dietary soybean beta-conglycinin.

Mitsutaka Kohno1, Motohiko Hirotsuka, Makoto Kito, Yuji Matsuzawa.   

Abstract

Soy protein isolate (SPI) is known to reduce the risk of heart disease by lowering serum cholesterol and triacylglycerol (TG) levels. Soybean beta-conglycinin, which is a component of SPI, might be the active ingredient that prevents and/or ameliorates lifestyle-related diseases, such as hyperlipidemia and obesity. This study aimed to determine the efficacy of soybean beta-conglycinin for lowering the human serum TG level and visceral fat. Randomized double-blind placebo-controlled designs were used to test the effect of dietary beta-conglycinin, which was taken in the form of candy. [Test 1]In order to examine the serum TG level, 138 volunteers aged 26 to 69 years with TG concentrations above 1.69 mmol/L participated in the study. The subjects were divided at random into two different groups: the test group only consumed the experimental candy containing beta-conglycinin and the placebo group only consumed the placebo candy containing casein. The test period consisted of a 2-wk pre-evaluation phase to screen the participants, a 12-wk consumption period and a 4-wk post-evaluation phase. The serum TG concentrations were significantly reduced in the test group, compared with the placebo group, after consuming the experimental candy. [Test 2]In order to measure visceral fat by means of CT scanning, 102 volunteers aged 26 to 69 years with body mass indices (BMI) between 25 and 30 participated in the study. The subjects were divided at random into two different groups as for Test 1. The test period consisted of a 2-wk pre-evaluation phase to screen the participants, a 20-wk consumption period and a 4-wk post-evaluation phase. A significant reduction in visceral fat only occurred in the beta-conglycinin group. This study showed that beta-conglycinin is an effective food ingredient that will be of use to reduce high serum TG concentrations and to prevent obesity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17146153     DOI: 10.5551/jat.13.247

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  28 in total

1.  In vitro screening for antihyperlipidemic activities in foodstuffs by evaluating lipoprotein profiles secreted from human hepatoma cells.

Authors:  Jyunichiro Takahashi; Gen Toshima; Yukie Matsumoto; Fumiko Kimura; Takanobu Kiuchi; Kentaro Hamada; Keishi Hata
Journal:  J Nat Med       Date:  2011-05-12       Impact factor: 2.343

2.  Consumption of different soymilk formulations differentially affects the gut microbiomes of overweight and obese men.

Authors:  Dina Fernandez-Raudales; Jennifer L Hoeflinger; Neal A Bringe; Stephen B Cox; Scot E Dowd; Michael J Miller; Elvira Gonzalez de Mejia
Journal:  Gut Microbes       Date:  2012-08-16

3.  A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults.

Authors:  Sonia Blanco Mejia; Mark Messina; Siying S Li; Effie Viguiliouk; Laura Chiavaroli; Tauseef A Khan; Korbua Srichaikul; Arash Mirrahimi; John L Sievenpiper; Penny Kris-Etherton; David J A Jenkins
Journal:  J Nutr       Date:  2019-06-01       Impact factor: 4.798

4.  Repressive effects of red bean, Phaseolus angularis, extracts on obesity of mouse induced with high-fat diet via downregulation of adipocyte differentiation and modulating lipid metabolism.

Authors:  Young Mi Park; Jee In Kim; Dong Hyun Seo; Joo Hee Seo; Jae-Hwan Lim; Jong Eun Lee; Je-Yong Choi; Eul-Won Seo
Journal:  Food Sci Biotechnol       Date:  2018-07-07       Impact factor: 2.391

5.  Intracerebroventricular administration of soy protein hydrolysates reduces body weight without affecting food intake in rats.

Authors:  Nerissa Vaughn; Anthony Rizzo; Dolores Doane; J Lee Beverly; Elvira Gonzalez de Mejia
Journal:  Plant Foods Hum Nutr       Date:  2007-12-23       Impact factor: 3.921

6.  Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions.

Authors:  Marguerite A Klein; Richard L Nahin; Mark J Messina; Jeanne I Rader; Lilian U Thompson; Thomas M Badger; Johanna T Dwyer; Young S Kim; Carol H Pontzer; Pamela E Starke-Reed; Connie M Weaver
Journal:  J Nutr       Date:  2010-04-14       Impact factor: 4.798

7.  The α' subunit of β-conglycinin and the A1-5 subunits of glycinin are not essential for many hypolipidemic actions of dietary soy proteins in rats.

Authors:  Qixuan Chen; Carla Wood; Christine Gagnon; Elroy R Cober; Judith A Frégeau-Reid; Stephen Gleddie; Chao Wu Xiao
Journal:  Eur J Nutr       Date:  2013-11-26       Impact factor: 5.614

Review 8.  Food and Nutrition in the Pathogenesis of Liver Damage.

Authors:  Andrea Mega; Luca Marzi; Michael Kob; Andrea Piccin; Annarosa Floreani
Journal:  Nutrients       Date:  2021-04-16       Impact factor: 5.717

9.  Does Glycine max leaves or Garcinia Cambogia promote weight-loss or lower plasma cholesterol in overweight individuals: a randomized control trial.

Authors:  Ji-Eun Kim; Seon-Min Jeon; Ki Hun Park; Woo Song Lee; Tae-Sook Jeong; Robin A McGregor; Myung-Sook Choi
Journal:  Nutr J       Date:  2011-09-21       Impact factor: 3.271

10.  β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.

Authors:  Ederlan S Ferreira; Maraiza A Silva; Aureluce Demonte; Valdir A Neves
Journal:  Lipids Health Dis       Date:  2012-01-13       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.